Illuccix® Approved in the United Kingdom
MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide...
Coreline Soft signs partnership with ParagonCare… Participation in ALCC 2025
Strategic partnership with Australian comprehensive healthcare company ParagonCare (ASX:PGC) Demonstration of global lung cancer screening optimization product AVIEW LCS Plus at ALCC 2025 to be held on the 19th Consulting based on experience in winning global lung cancer screening orders in Germany, Italy, and 5 European countries ADELAIDE, Australia and...
NEOM Investment Fund partners with Paradromics to drive innovation in neurotechnology healthcare
Strategic partnership with Paradromics will accelerate advancements in brain-computer interfaces and establish a Center of Excellence in NEOM. AUSTIN, Texas, Feb. 13, 2025 /PRNewswire/ -- Paradromics, Inc., a global leader in high-data rate brain-computer interface (BCI) technology, announced a strategic investment from NEOM, the sustainable region taking shape in northwest Saudi Arabia. The Paradromics Cortical Module is...
TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients’ Access to Life-Changing Medicines
Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan. CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/ -- TriNetX, a global leader in real-world data (RWD) and real-world evidence (RWE) solutions, has partnered with Fujitsu, a global ICT company and one of Japan's leading electronic health record (EHR) vendors, to form...
Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the publication of its most recent peer-reviewed journal article entitled Clinical Pharmacology and Approach...
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting Antibody-Drug Conjugate (CDH6 ADC) and the company's lead program, for...
Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management- Recognition reflects Samsung Biologics' commitment to water security and implementing sustainable practices across operations INCHEON, South Korea, Feb. 12, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that it has received...
Mizuchan: Pioneering Clean Water Solutions for a Sustainable Future
Transforming Lives with Clean Water HO CHI MINH CITY, Vietnam, Feb. 12, 2025 /PRNewswire/ -- In a small rural village in southern Vietnam, access to clean water was once a distant dream. Families depended on rainwater and murky streams, exposing themselves to severe health risks. Everything changed when Mizuchan stepped in. By introducing modern filtration systems and a steadfast commitment...
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for clinical trials to the Center for Drug Evaluation (CDE) of the PRC's National Medical Products Administration. Preclinical studies have demonstrated that the vaccine exhibits...
Lion TCR’s Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This significant progress further solidifies Lion TCR's leading position...
